



## 89bio to Participate in the UBS Global Healthcare Conference

November 5, 2024

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.

The webcast of the presentation will be accessible in the investor section of [89bio's website](#). A replay of the webcast will be available for approximately 30 days following the conference.

### About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit [www.89bio.com](http://www.89bio.com) or follow the company on [LinkedIn](#).

### Investor Contact:

Annie Chang  
89bio, Inc.  
[investors@89bio.com](mailto:investors@89bio.com)

PJ Kelleher  
LifeSci Advisors, LLC  
617-430-7579  
[pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)

### Media Contact:

Sheryl Seapy  
Real Chemistry  
[sseapy@realchemistry.com](mailto:sseapy@realchemistry.com)